UniProt Q86V86 · PDB · AlphaFold · Substrate: Pim2tide · Clone: full lengthmedium-confidence target
Top inhibitors
| # | Drug | Inhibition | Residual | KISS | Gini |
|---|---|---|---|---|---|
| 1 | Abemaciclib | 100.0% | 0.0% | 91.48 | 0.563 |
| 2 | Alectinib | 95.1% | 4.9% | 95.49 | 0.651 |
| 3 | Midostaurin | 70.9% | 29.1% | 78.64 | 0.500 |
| 4 | Dacomitinib | 50.4% | 49.6% | 97.99 | 0.664 |
| 5 | Defactinib | 45.9% | 54.1% | 92.68 | 0.450 |
| 6 | Gilteritinib | 45.4% | 54.6% | 88.97 | 0.506 |
| 7 | Rabusertib | 40.3% | 59.7% | 98.74 | 0.687 |
| 8 | Sunitinib | 39.4% | 60.6% | 91.73 | 0.524 |
| 9 | Ponatinib | 29.0% | 71.0% | 78.23 | 0.534 |
| 10 | Canertinib | 23.3% | 76.7% | 96.49 | 0.671 |
| 11 | Bosutinib | 22.9% | 77.1% | 87.22 | 0.555 |
| 12 | Avapritinib | 19.8% | 80.2% | 97.73 | 0.644 |
| 13 | Gefitinib | 19.2% | 80.8% | 99.25 | 0.650 |
| 14 | Palbociclib | 15.6% | 84.4% | 98.75 | 0.673 |
| 15 | Darovasertib | 14.8% | 85.2% | 96.99 | 0.719 |
| 16 | Pacritinib | 12.1% | 87.9% | 88.64 | 0.452 |
| 17 | Ceritinib | 8.4% | 91.6% | 95.44 | 0.618 |
| 18 | Tenalisib | 7.2% | 92.8% | 97.98 | 0.702 |
| 19 | Crizotinib | 6.2% | 93.8% | 91.39 | 0.581 |
| 20 | Erlotinib | 6.0% | 94.0% | 99.75 | 0.695 |
Paralog block
No paralog group registered for this kinase.
EMT expression
- Mesenchymal log2(TPM+1): 4.01
- Epithelial log2(TPM+1): 4.98
- Fold change: -0.97
- Status: No significant change
High-confidence drugs
- Abemaciclib — inh 100.0% · KISS 37.38
- Alectinib — inh 95.1% · KISS 37.24
- Midostaurin — inh 70.9% · KISS -0.14
Selectivity landscape vs inhibition on PIM3
Each point is one of the 92 approved drugs; color = inhibition % on PIM3.
3D structure
Embedded NGL viewer pulls a representative PDB entry (or AlphaFold model if no experimental structure is registered). Heavy bundle — loaded only on demand.
Annotations
Sign in to read and post annotations.
Loading…